



Cite this: *Org. Biomol. Chem.*, 2017, **15**, 373

## Carbonylation as a novel method for the assembly of pyrazine based oligoamide $\alpha$ -helix mimetics†

Segeer Van Mileghem,<sup>†a</sup> Brecht Egle,<sup>†a</sup> Philippe Gilles,<sup>a</sup> Cedrick Veryser,<sup>a</sup> Luc Van Meervelt<sup>b</sup> and Wim M. De Borggraeve<sup>\*a</sup>

The design and synthesis of oligoamide  $\alpha$ -helix peptidomimetics is reported. The oligoamide type systems are prepared in a modular fashion by coupling the monomers using palladium-catalyzed carbonylation chemistry. This enabled us to use substrates with a low nucleophilicity, leading to previously unreported pyrazine based oligoamide  $\alpha$ -helix mimetics. The proof of principle is given by synthesizing a small set of compounds. Various end-capping groups were introduced and also a mixed multimer was successfully prepared.

Received 30th October 2016,  
Accepted 29th November 2016

DOI: 10.1039/c6ob02358d

www.rsc.org/obc

## Introduction

Protein–protein interactions (PPI), because of their importance in biological processes, are interesting though difficult targets for potential therapeutic applications. With good reason PPI were once considered undruggable, mostly because of their large (1500–3000 Å<sup>2</sup>) and shallow but dynamic interaction surfaces.<sup>1</sup> Fortunately, in most cases, the interaction is highly dependent on just a small number of key amino acid residues. These are located on the interaction surface, forming a so called hot spot.<sup>2</sup> Currently, the number of small molecule protein–protein interaction inhibitors is increasing.<sup>1,3–5</sup> Analysis of multiprotein complexes in the Protein Data Bank by the Arora group has shown that in more than 60% of the cases,  $\alpha$ -helices are present in the interaction surfaces.<sup>6</sup> Hence, mimetics of this secondary structure element show significant medicinal potential. Due to the nature of PPIs, small molecules targeting these interactions can lie beyond Lipinski's rule of five.<sup>7</sup> Several approaches exist where the helical backbone is replaced by a small molecule core decorated with amino acid side chains in the same spatial positions as in an  $\alpha$ -helix at relative positions  $i$ ,  $i + 3$ ,  $i + 4$ ,  $i + 7$  of the  $\alpha$ -helix. A multitude of such minimalist peptidomimetics<sup>8–18</sup> have been

reported in the last two decades. A remarkable class of molecules are the oligoamide systems which have shown potency in the modulation of protein–protein interactions.<sup>19</sup>

Central in the design of these oligoamide systems is the modularity in synthesis. This elegant concept provides an unambiguous strategy for the assembly of monomeric units to multimers. Among the oligoamide type systems described in the literature (some examples in ref. 20–23 and Scheme 1A), amide bond formation is not always straightforward.<sup>24</sup> The amide synthesis is typically performed *via* acyl chlorides or *via* the corresponding carboxylic acid with specialty coupling reagents (e.g. Ph<sub>3</sub>PCl<sub>2</sub>,<sup>25</sup> Ghosez's reagent<sup>26</sup> and Mukaiyama reagent<sup>27</sup>) since the amine coupling partners are not always nucleophilic. Due to the elaborate synthetic work, significant efforts have been made towards solid phase synthesis and recently, late stage introduction of the amino acid residues.<sup>26,28</sup>

Here, we report on palladium-catalyzed carbonylation as an alternative strategy for the assembly of monomers (Scheme 1B). The use of catalytic carbonylation chemistry as a coupling method is advantageous since (1) no stoichiometric amounts of coupling reagents are used, (2) it offers a broad functional group tolerance and (3) it is able to handle substrates which are very low in nucleophilicity.<sup>29</sup>

Previous experience with peptidomimetics<sup>30</sup> and carbonylation<sup>31</sup> in our group motivated us to combine this knowledge to pursue the synthesis of unreported pyrazine based oligoamide  $\alpha$ -helix peptidomimetics *via* palladium-catalyzed carbonylation. This scaffold has the interesting feature of increasing hydrophilicity and solubility by adding hydrogen bond acceptors that can contribute to a so called wet edge.<sup>32,33</sup> The modularity in design by using carbonylation chemistry enabled us to synthesize both pyrazine based multimers as well as a hybrid dimer.


<sup>a</sup>Molecular Design and Synthesis, Department of Chemistry, KU Leuven, Celestijnenlaan 200F, box 2404, B-3001 Leuven, Belgium

<sup>b</sup>Biochemistry, Molecular and Structural Biology, Department of Chemistry, KU Leuven, Celestijnenlaan 200F, box 2404, B-3001 Leuven, Belgium.  
E-mail: wim.deborggraeve@kuleuven.be

†Electronic supplementary information (ESI) available. CCDC 1512412–1512414. For ESI and crystallographic data in CIF or other electronic format see DOI: 10.1039/c6ob02358d

‡These authors contributed equally.






**Scheme 1** (A) An  $\alpha$ -helix next to known oligoamide type helix mimetics. (B) Our proposed strategy towards pyrazine based peptidomimetics.

## Results and discussion

### Retrosynthesis

It was proposed that the pyrazine based multimeric structure (Scheme 2) mimics the amino acid residues at the same face of the helix as its phenyl and pyridine counterparts,<sup>34</sup> namely at the  $i$ ,  $i + 4$  and  $i + 7$  positions. Building block **1** (or its protected version **2**) consists of a pyrazine core which enabled the development of a modular route (Scheme 2). The idea is inspired by peptide synthesis where a sequence of activation, coupling and deprotection is repeated a number of times to synthesize (oligo)peptides. Similarly, in our strategy, building blocks **2** serve as a substrate for the growing oligoamide multimers *via* a palladium-catalyzed carbonylation with CO gas,<sup>35</sup> which are then deprotected to prepare them for the next coupling. The main reason for using aminocarbonylation as the coupling methodology is due to its ability to couple substrates which are low in nucleophilicity, such as aminopyrazine derivatives.<sup>36</sup> Moreover, the reaction conditions of carbonylation chemistry are mild and therefore compatible with sensitive amino acid side chains present on the peptidomimetics.<sup>35</sup> We recently reported a carbon monoxide precursor system based on the elegant two-chamber setup of the Skrydstrup group.<sup>31,37</sup> In order to avoid the use of a CO lecture bottle and CO filled balloons, this setup was successfully used in a later



**Scheme 2** Retrosynthetic approach to pyrazine based trimers.

stage for carbonylation couplings for the sake of safety (see the ESI†).

In order to avoid homocoupling and polymerization, the first building block needs to have its halide group replaced with a moiety that cannot interfere in the following palladium-catalyzed coupling. This is a so called end-capping group, which in the peptide synthesis analogy corresponds to blocking the C-terminal amino acid by formation of *e.g.* an ester or attachment to a solid support. The end-capping can be done *via* carbonylation chemistry or other cross-coupling chemistry, such as Suzuki coupling<sup>38</sup> forming biaryl type compounds ( $Y = Ar$ ). Deprotection of an end-capped scaffold yields **4** that is ready to be coupled with another Boc-protected building block (**2**) *via* carbonylation. Finally, another iteration of the deprotection/coupling followed by a final deprotection yields the pyrazine based  $\alpha$ -helix peptidomimetic trimer (**8**). To demonstrate this proof of principle, a range of monomeric building blocks was synthesized which were assembled into a set of multimers.

The Boc-protected aminopyrazines (**2**, Scheme 2) allow easy preparation of mixed multimers, containing both pyrazine and other types of monomers (*e.g.* phenyl scaffolds). This not only increases the potential structural diversity but also allows tuning the conformational rigidity of the multimers, which has been demonstrated to be advantageous for some PPI targets.<sup>39</sup>

### Synthesis

In a first stage the synthesis of pyrazine building blocks is performed (Table 1). Aminopyrazine is dibrominated using NBS in DMSO.<sup>40</sup> Following bromination, the desired amino acid mimicking side chain<sup>41</sup> was attached using a fully regioselective  $S_NAr$  in THF.<sup>40,42</sup> Table 1 summarizes the scope of the synthesized pyrazine building blocks. Monomers **1a–d** were prepared in excellent yields. Following the synthesis of the monomers, we embarked upon the assembly of multimers. Some examples are depicted in Scheme 3. After Boc-protection




**Table 1** Synthesis of the pyrazine building blocks<sup>a</sup>

Entry	Base	Product	Yield (%)	AA residue
1a <sup>b</sup>	NaH		83	Ala
1b	NaHMDS		88	Leu
1c	NaH		81	Phe
1d <sup>c</sup>	NaH		91	Val

<sup>a</sup> Conditions: 0.2 M pyrazine in THF, 1.5 eq. alcohol, 1.5 eq. base, 50 °C, overnight. <sup>b</sup> 1.1 eq. NaOMe in MeOH. <sup>c</sup> 10 eq. iPrOH and 3 eq. NaH.


of **1**, an alkoxyacylation was performed to synthesize methyl ester end-capped building blocks **3** in good yields. Subsequently, the Boc groups were removed under acidic conditions. In a following step dimers **5a** and **5b** were synthesized and subsequently deprotected. The last two steps were repeated to obtain trimers **8a** and **8b**.

X-ray analysis of **6b** confirms the presence of intramolecular hydrogen bonds, in analogy to the oligoamide pyridine counterparts.<sup>34</sup> An overlay image of our dimer **6b** with a benzamide<sup>43</sup> and pyridine analog<sup>44</sup> is shown in Fig. 1 (see the ESI† for the refined structure with the according thermal




**Fig. 1** Overlay analysis of Wilson's benzamide crystal (CCDC 870274), Hamilton's pyridine crystal (CCDC 697087) and our pyrazine crystal (CCDC 1512413).

ellipsoids). It was observed that the distance between the *O*-alkylated side chains is slightly smaller than is observed for the benzamide system (Fig. 1). This is a result of the additional hydrogen bond between the amide proton and pyrazine nitrogen, as was also the case for the pyridine dimer.<sup>44</sup> The presence of this hydrogen bond is also responsible for the stronger downfield shift of the amide proton in comparison with the one in our hybrid system (10.09 ppm for **10** vs. 8.45 ppm for **14**) and the benzamide and pyridinyl amide systems described in the literature.<sup>34,44</sup> Furthermore, a smaller angle of inclination is observed (155.9° versus 159.6° for our pyrazine system and the reported benzamide system, respectively). This



**Scheme 3** Synthesis of pyrazine based methyl ester end-capped  $\alpha$ -helix peptidomimetics. Reagents and conditions: (a) Boc<sub>2</sub>O, DMAP, DCM, reflux. (b) MeOH, Pd(OAc)<sub>2</sub>, xantphos, CO, Et<sub>3</sub>N, 80 °C. (c) TFA, DCM or H<sub>2</sub>O, reflux. (d) **2a** or **2b**, Pd(OAc)<sub>2</sub>, xantphos, CO, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C. (e) TFA, DCM or H<sub>2</sub>O, reflux. (f) **2a**, **2b** or **2c**, Pd(OAc)<sub>2</sub>, xantphos, CO, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C. (g) TFA, DCM.






**Scheme 4** Synthesis of pyrazine based Suzuki end-capped  $\alpha$ -helix peptidomimetics. Reagents and conditions: (a) (3-methoxyphenyl)boronic acid, Pd(OAc)<sub>2</sub>, K<sub>2</sub>CO<sub>3</sub>, S-Phos, ACN : H<sub>2</sub>O, 100 °C, 73%. (b) 1. 2c, Pd(OAc)<sub>2</sub>, xantphos, CO, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C, 21%. 2. TFA, DCM, Quant.

clearly shows the structural resemblance between our and known systems. However, a more exact evaluation of which residues in a helix can be mimicked by these scaffolds would require a more detailed analysis (EKOS).<sup>45</sup>


In the case of dimer formation, an amount up to 30% of Buchwald–Hartwig amination<sup>46</sup> side product was observed. This was confirmed by X-ray crystallography (see the ESI†). For the synthesis of **5b**, the amination product (**5b'**, not shown) was isolated in 29% yield. These findings correlate with a report of Buchwald *et al.*,<sup>47</sup> describing that in a palladium/xantphos system the preferred reaction conditions are electron deficient aryl halides combined with electron deficient nucleophiles, which is the case for our pyrazine substrates. On the other hand, the low trimer formation yields might be due to the poor solubility of the dimers in toluene, since significant amounts of the starting materials were recovered. Other solvents commonly used in carbonylation chemistry (such as dioxane, THF and DMF) did not improve the yield of these reactions.

In a next example, Suzuki cross coupling was used as end-capping chemistry. This is demonstrated in Scheme 4. Building block **1a** was end-capped to obtain compound **9**. Boc-protected building block **2c** was attached *via* carbonylation, which after deprotection led to dimer **10**. Alternatively, other aryl building blocks can also be introduced as the second monomeric unit *via* this modular synthesis. This is demonstrated in Scheme 5. Phenyl monomer **13** was synthesized starting from *p*-nitrobromobenzene (**11**) *via* a vicarious nucleophilic substitution which was carried out in a mixture of THF and liquid ammonia.<sup>48</sup> The resulting phenol **12** was treated with *p*-fluorobenzyl alcohol in a Mitsunobu reaction to yield **13**.<sup>49</sup> Finally, this monomer was coupled with **9**, which gave rise to hybrid dimer **14**.

Similar to the reported oligoamide systems, the water solubility of our multimers remains problematic. However, the introduction of a water solubilizing end capping group is possible *via* the carbonylation strategy. When end-capping **2d** with *N*-methylpiperazine (not shown), only traces of the desired product were obtained. As it appears, secondary amines react with anilinic carbamate groups, forming unsymmetrical ureas



**Scheme 5** Synthesis of a hybrid dimer containing both a phenyl and pyrazine moiety. Reagents and conditions: (a) cumene hydroperoxide, NH<sub>3</sub> : THF, −33 °C, 57%. (b) *p*-Fluorobenzyl alcohol, PPh<sub>3</sub>, DIAD, THF, 62%. (c) **9**, Pd(OAc)<sub>2</sub>, xantphos, CO, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C, 65%.



**Scheme 6** Synthesis of dimer HCl salt by piperazine end-cap. Reagents and conditions: (a) *N*-methylpiperazine, Pd(OAc)<sub>2</sub>, xantphos, CO, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C. (b) 1. **2b**, Pd(OAc)<sub>2</sub>, xantphos, CO, Na<sub>2</sub>CO<sub>3</sub>, toluene, 100 °C, 17% (43% with recovery of **15a**). 2. TFA, DCM, 97%. 3. HCl, dioxane, quant.

at elevated temperatures and deprotecting the pyrazine.<sup>50</sup> Fortunately, when performing this carbonylation with unprotected monomer **1d**, the end-capped product **15a** was obtained (Scheme 6). A similar result was achieved when using monomer **1a**. Compound **15a** was then coupled with **2b**. After deprotection this gave **16**, which mimics an  $\alpha$ -helix with valine and leucine residues. The water solubility problem was however not solved by introducing the piperazine moiety.

## Conclusion

In conclusion, a modular synthesis protocol has been developed towards previously unreported oligoamide pyrazine based  $\alpha$ -helix peptidomimetics, as well as a hybrid type derivative. A coupling–deprotection sequence was used, utilizing a palladium-catalyzed aminocarbonylation to form the amide bonds between poorly nucleophilic aminopyrazine type building blocks. This methodology enables the flexible synthesis of a diverse set of (hetero)aryl oligoamide  $\alpha$ -helix peptidomimetics. The synthesis also features the introduction of various end capping groups *via* (carbonylative) cross coupling reactions. Attempts to improve trimer formation yields are currently in progress.





## Acknowledgements

We are grateful to K. Duerinckx for the NMR measurements and to prof. Dr Jef Rozenski for HR-MS measurements. CV and BE thank FWO for PhD fellowships received. WDB thanks KU Leuven for financial support *via* project OT/14/067. LVM thanks the Hercules Foundation for supporting the purchase of the diffractometer through project AKUL/09/0035.

## Notes and references

- 1 A. Voet, E. F. Banwell, K. K. Sahu, J. G. Heddle and K. Y. J. Zhang, *Curr. Top. Med. Chem.*, 2013, **13**, 989–1001.
- 2 T. Clackson and J. A. Wells, *Science*, 1995, **267**, 383–386.
- 3 V. Azzarito, K. Long, N. S. Murphy and A. J. Wilson, *Nat. Chem.*, 2013, **5**, 161–173.
- 4 L. Y. Jin, W. R. Wang and G. W. Fang, *Annu. Rev. Pharmacol. Toxicol.*, 2014, **54**, 435–456.
- 5 M. R. Arkin, Y. Y. Tang and J. A. Wells, *Chem. Biol.*, 2014, **21**, 1102–1114.
- 6 B. N. Bullock, A. L. Jochim and P. S. Arora, *J. Am. Chem. Soc.*, 2011, **133**, 14220–14223.
- 7 B. C. Doak, J. Zheng, D. Dobritzsch and J. Kihlberg, *J. Med. Chem.*, 2016, **59**, 2312–2327.
- 8 Z. C. Zhang, X. Q. Li, T. Song, Y. Zhao and Y. G. Feng, *J. Med. Chem.*, 2012, **55**, 10735–10741.
- 9 W. Antuch, S. Menon, Q. Z. Chen, Y. C. Lu, S. Sakamuri, B. Beck, V. Schauer-Vukasinovic, S. Agarwal, S. Hess and A. Dömling, *Bioorg. Med. Chem. Lett.*, 2006, **16**, 1740–1743.
- 10 J. Becerril and A. D. Hamilton, *Angew. Chem., Int. Ed.*, 2007, **46**, 4471–4473.
- 11 M. D. Cummings, C. Schubert, D. J. Parks, R. R. Calvo, L. V. LaFrance, J. Lattanze, K. L. Milkiewicz and T. B. Lu, *Chem. Biol. Drug Des.*, 2006, **67**, 201–205.
- 12 H. Yin, G. I. Lee, H. S. Park, G. A. Payne, J. M. Rodriguez, S. M. Sebt and A. D. Hamilton, *Angew. Chem., Int. Ed.*, 2005, **44**, 2704–2707.
- 13 H. Yin, G. I. Lee, K. A. Sedey, O. Kutzki, H. S. Park, B. P. Omer, J. T. Ernst, H. G. Wang, S. M. Sebt and A. D. Hamilton, *J. Am. Chem. Soc.*, 2005, **127**, 10191–10196.
- 14 H. Yin, B. P. Orner, H. S. Park and A. D. Hamilton, *Abstr. Pap., Am. Chem. Soc.*, 2002, **224**, U133–U133.
- 15 H. Moon and H.-S. Lim, *Curr. Opin. Chem. Biol.*, 2015, **24**, 38–47.
- 16 V. Azzarito, J. A. Miles, J. Fisher, T. A. Edwards, S. L. Warriner and A. J. Wilson, *Chem. Sci.*, 2015, **6**, 2434–2443.
- 17 S. Rodriguez-Marin, N. S. Murphy, H. J. Shepherd and A. J. Wilson, *RSC Adv.*, 2015, **5**, 104187–104192.
- 18 M. K. P. Jayatunga, S. Thompson and A. D. Hamilton, *Bioorg. Med. Chem. Lett.*, 2014, **24**, 717–724.
- 19 P. Ravindranathan, T. K. Lee, L. Yang, M. M. Centenera, L. Butler, W. D. Tilley, J. T. Hsieh, J. M. Ahn and G. V. Raj, *Nat. Commun.*, 2013, **4**, 1923.
- 20 O. V. Kulikov, S. Kumar, M. Magzoub, P. C. Knipe, I. Saraogi, S. Thompson, A. D. Miranker and A. D. Hamilton, *Tetrahedron Lett.*, 2015, **56**, 3670–3673.
- 21 O. V. Kulikov, S. Thompson, H. Xu, C. D. Incarvito, R. T. W. Scott, I. Saraogi, L. Nevola and A. D. Hamilton, *Eur. J. Org. Chem.*, 2013, 3433–3445.
- 22 S. Marimganti, M. N. Cheemala and J. M. Ahn, *Org. Lett.*, 2009, **11**, 4418–4421.
- 23 N. S. Murphy, P. Prabhakaran, V. Azzarito, J. P. Plante, M. J. Hardie, C. A. Kilner, S. L. Warriner and A. J. Wilson, *Chem. – Eur. J.*, 2013, **19**, 5546–5550.
- 24 G. M. Burslem and A. J. Wilson, *Synlett*, 2014, 324–335.
- 25 J. Plante, F. Campbell, B. Malkova, C. Kilner, S. L. Warriner and A. J. Wilson, *Org. Biomol. Chem.*, 2008, **6**, 138–146.
- 26 F. Campbell, J. P. Plante, T. A. Edwards, S. L. Warriner and A. J. Wilson, *Org. Biomol. Chem.*, 2010, **8**, 2344–2351.
- 27 O. V. Kulikov and A. D. Hamilton, *RSC Adv.*, 2012, **2**, 2454–2461.
- 28 G. M. Burslem, H. F. Kyle, P. Prabhakaran, A. L. Breeze, T. A. Edwards, S. L. Warriner, A. Nelson and A. J. Wilson, *Org. Biomol. Chem.*, 2016, **14**, 3782–3786.
- 29 J. R. Martinelli, D. A. Watson, D. M. M. Freckmann, T. E. Barder and S. L. Buchwald, *J. Org. Chem.*, 2008, **73**, 7102–7107.
- 30 W. M. De Borggraeve, B. M. P. Verbist, F. J. R. Rombouts, V. G. Pawar, W. J. Smets, L. Kamoune, J. Alen, E. V. Van der Eycken, F. Compennolle and G. J. Hoornaert, *Tetrahedron*, 2004, **60**, 11597–11612.
- 31 C. Veryser, S. Van Mileghem, B. Egle, P. Gilles and W. M. De Borggraeve, *React. Chem. Eng.*, 2016, **1**, 142–146.
- 32 S. M. Biro, L. Moisan, E. Mann, A. Carella, D. Zhai, J. C. Reed and J. Rebek, *Bioorg. Med. Chem. Lett.*, 2007, **17**, 4641–4645.
- 33 P. Prabhakaran, A. Barnard, N. S. Murphy, C. A. Kilner, T. A. Edwards and A. J. Wilson, *Eur. J. Org. Chem.*, 2013, 3504–3512.
- 34 J. T. Ernst, J. Becerril, H. S. Park, H. Yin and A. D. Hamilton, *Angew. Chem., Int. Ed.*, 2003, **42**, 535–539.
- 35 A. Brennfuhrer, H. Neumann and M. Beller, *Angew. Chem., Int. Ed.*, 2009, **48**, 4114–4133.
- 36 V. Theodorou, M. Gogou, A. Giannoussi and K. Skobridis, *ARKIVOC*, 2014, 11–23.
- 37 P. Hermange, A. T. Lindhardt, R. H. Taaning, K. Bjerglund, D. Lupp and T. Skrydstrup, *J. Am. Chem. Soc.*, 2011, **133**, 6061–6071.
- 38 A. Suzuki, *J. Organomet. Chem.*, 1999, **576**, 147–168.
- 39 J. L. Yap, X. B. Cao, K. Vanommeslaeghe, K. Y. Jung, C. Peddaboina, P. T. Wilder, A. Nan, A. D. MacKerell, W. R. Smythe and S. Fletcher, *Org. Biomol. Chem.*, 2012, **10**, 2928–2933.
- 40 B. Jiang, C. G. Yang, W. N. Xiong and J. Wang, *Bioorg. Med. Chem.*, 2001, **9**, 1149–1154.
- 41 G. A. Patani and E. J. LaVoie, *Chem. Rev.*, 1996, **96**, 3147–3176.



- 42 S. Scales, S. Johnson, Q. Y. Hu, Q. Q. Do, P. Richardson, F. Wang, J. Braganza, S. J. Ren, Y. D. Wan, B. J. Zheng, D. Faizi and I. McAlpine, *Org. Lett.*, 2013, **15**, 2156–2159.
- 43 V. Azzarito, P. Prabhakaran, A. I. Bartlett, N. S. Murphy, M. J. Hardie, C. A. Kilner, T. A. Edwards, S. L. Warriner and A. J. Wilson, *Org. Biomol. Chem.*, 2012, **10**, 6469–6472.
- 44 I. Saraogi, C. D. Incarvito and A. D. Hamilton, *Angew. Chem., Int. Ed.*, 2008, **47**, 9691–9694.
- 45 D. Y. Xin, E. Ko, L. M. Perez, T. R. Ioerger and K. Burgess, *Org. Biomol. Chem.*, 2013, **11**, 7789–7801.
- 46 A. S. Guram, R. A. Rennels and S. L. Buchwald, *Angew. Chem., Int. Ed. Engl.*, 1995, **34**, 1348–1350.
- 47 M. C. Harris, O. Geis and S. L. Buchwald, *J. Org. Chem.*, 1999, **64**, 6019–6022.
- 48 M. Makosza and K. Sienkiewicz, *J. Org. Chem.*, 1998, **63**, 4199–4208.
- 49 B. H. Lipshutz, D. W. Chung, B. Rich and R. Corral, *Org. Lett.*, 2006, **8**, 5069–5072.
- 50 M. Lamothe, M. Perez, V. Colovray-Gotteland and S. Halazy, *Synlett*, 1996, 507–508.

